A Phase II Study Assessing the Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
Latest Information Update: 24 Jun 2024
Price :
$35 *
At a glance
- Drugs Enzalutamide (Primary) ; Testosterone undecanoate (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 06 May 2022 Status changed from not yet recruiting to recruiting.
- 02 Mar 2022 Planned initiation date changed from 15 Feb 2022 to 31 Mar 2022.
- 05 Jan 2022 Planned initiation date changed from 1 Dec 2021 to 15 Feb 2022.